Published September 29, 2024 | Version 01
Dataset Open

Healthcare Expenditure and Demographic Trends: A Comparative Analysis of Selected Countries (2000-2024)

Authors/Creators

  • 1. ACI HealthCare Limited

Description

This research journal investigates the interplay between healthcare expenditure, life expectancy, and demographic characteristics across selected countries from 2000 to 2024. Utilizing quantitative analysis, the study examines healthcare spending as a percentage of GDP, average life expectancy, and the age distribution of populations. For instance, the USA's healthcare expenditure is projected to reach 19.2% of GDP by 2024, with an average life expectancy of 81.9 years. In contrast, Bangladesh's healthcare expenditure is anticipated to be 7.0% of GDP, with a life expectancy of 70.0 years. The findings reveal critical insights regarding the effectiveness and sustainability of healthcare systems, emphasizing the need for policy interventions that prioritize healthcare funding, especially in aging populations where the percentage of individuals aged 65 and older is expected to rise significantly—projected at 16.0% for the USA and 7.0% for Bangladesh in 2024.

Files

Files (57.2 kB)

Name Size
md5:2922584578a098046a33e9ef51d462d7
57.2 kB Download

Additional details

References

  • Alam, A. M. ul . (2024). Advancing Generic Drug Development: A Comprehensive Approach to Azacitidine Bioequivalence Studies. Zenodo. https://doi.org/10.5281/zenodo.10579212
  • World Bank. (2023). World Development Indicators. Retrieved from World Bank Data
  • World Health Organization. (2023). Global Health Expenditure Database. Retrieved from WHO Health Expenditure
  • Organisation for Economic Co-operation and Development. (2023). Health at a Glance. Retrieved from OECD Health Data
  • OpenAI. (2024). ChatGPT (v. 3.5) [AI language model]. https://openai.com/chatgpt
  • United Nations. (2023). World Population Prospects. Retrieved from UN Population Division
  • CIA World Factbook. (2023). Country Profiles. Retrieved from CIA Factbook
  • Alam, A. M. ul . (2024). Comprehensive Risk Assessment of Potent API Exposure in Solid Dosage Form Production Using FMEA Methodology (Version 01) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.13765480
  • Alam, A. M. ul . (2024). Extensive Checklist to cGMP Inspections in Pharmaceutical Manufacturing Plants (Version 01) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.13764776
  • Alam, A. M. ul . (2024). A Comprehensive Review of ANDA Submissions and Amendments Under GDUFA: FDA Guidelines for the Generic Drug Industry (Version 01) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.13760042
  • Alam, A. M. ul . (2024). Next-Gen Quality Assurance: A Deep Dive into Integrating Artificial Intelligence in the Pharmaceutical Industry [Data set]. Zenodo. https://doi.org/10.5281/zenodo.13739653
  • Alam, A. M. ul . (2024). Comprehensive Evaluation of Alternative API, Excipient, and Packaging Material Sources: A Regulatory Perspective (Version 01, pp. 1–16) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.13739484
  • Alam, A. M. ul . (2023). A QBD based RP-HPLC Method Development and Validation for Quantification of Pregabalin Capsules [Data set]. In A QBD based RP-HPLC Method Development and Validation for Quantification of Pregabalin Capsules (Version 01, Vol. 12, Number 11, pp. 948–955). International Journal of Science and Research (IJSR). https://doi.org/10.21275/SR231112082256
  • Alam, A. M. ul . (2024). Evolution of FDA Guidelines on Control of Nitrosamine Impurities in Human Drugs – A Comparative Analysis of September 2024 Revisions (Version 01) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.13685540